|1.||Horowitz, John D: 9 articles (05/2014 - 03/2004)|
|2.||Frenneaux, Michael P: 6 articles (08/2015 - 01/2007)|
|3.||Frenneaux, Michael: 5 articles (09/2015 - 11/2005)|
|4.||Horowitz, John: 4 articles (03/2015 - 11/2005)|
|5.||Ashrafian, Houman: 4 articles (02/2015 - 11/2005)|
|6.||Pagano, Domenico: 3 articles (09/2015 - 05/2014)|
|7.||Howell, Neil J: 3 articles (09/2015 - 05/2014)|
|8.||Drury, Nigel E: 3 articles (09/2015 - 05/2014)|
|9.||Beadle, Roger M: 3 articles (08/2015 - 01/2011)|
|10.||Abozguia, Khalid: 3 articles (03/2015 - 09/2009)|
01/01/2007 - "We discuss how therapeutic plasma monitoring has led to perhexiline's safe reintroduction into clinical practice and how recent clinical data attesting to its safety and remarkable efficacy led to a renaissance in its use in both refractory angina and chronic heart failure. "
11/22/2005 - "Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment."
03/01/2015 - "Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy."
03/01/2015 - "The aim of this study was to determine whether short-term treatment with perhexiline improves cardiac energetics, left ventricular function, and symptoms of heart failure by altering cardiac substrate utilization. "
11/01/2014 - "Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome."
05/01/1981 - "Perhexiline in a dose of 200 mg daily is effective against angina pectoris and significantly increases exercise tolerance. "
10/01/1978 - "Despite the greater efficacy of perhexiline, it is suggested that side effects should preclude its routine prescription as a drug of first choice in angina pectoris. "
01/01/2001 - "However, there is a paucity of trials demonstrating the efficacy of low dosages of perhexiline (100 to 200 mg/day) in patients with refractory angina pectoris. "
05/01/1983 - "This study shows that the addition of perhexiline to beta-adrenoreceptor antagonists in patients with severe angina pectoris is effective and represents an alternative therapy."
10/01/2009 - "Perhexiline is a drug that is used for treatment of moderate to severe angina pectoris that has not responded to other treatment. "
|3.||Acute Coronary Syndrome
06/01/2004 - "Perhexiline is a prophylactic anti-anginal agent that ameliorates the metabolic basis for myocardial ischaemia and is increasingly used in the management of acute coronary syndromes. "
06/01/2004 - "Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes."
02/15/2006 - "The prophylactic anti-anginal agent, perhexiline, may also be effective in acute coronary syndromes and advanced aortic valvular stenosis, conditions associated with enhanced inflammation. "
12/01/1996 - "We conclude that this study (a) suggests that PM exerts incremental antianginal effects over those of other antiischaemic agents in patients with acute coronary syndromes and (b) establishes that the development of nausea and/or dizziness in such patients is strongly predictive of accumulation of perhexiline beyond the therapeutic range of the drug."
03/29/2007 - "Perhexiline, a "metabolic" anti-anginal agent currently under investigation in management of congestive heart failure and acute coronary syndromes improves platelet nitric oxide responsiveness in patients with impaired responsiveness. "
|4.||Hypertrophic Cardiomyopathy (Asymmetric Septal Hypertrophy)
02/01/2011 - "The metabolic modulator perhexiline improves myocardial diastolic energetics to achieve significant symptomatic improvement in hypertrophic cardiomyopathy. "
10/19/2010 - "In symptomatic hypertrophic cardiomyopathy, perhexiline, a modulator of substrate metabolism, ameliorates cardiac energetic impairment, corrects diastolic dysfunction, and increases exercise capacity. "
02/01/2015 - "Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy."
01/01/2011 - "Metabolic myocardial modulation with perhexilene significantly enhances effort tolerance in hypertrophic cardiomyopathy. "
10/19/2010 - "Forty-six consecutive patients with symptomatic exercise limitation (peak Vo(2) <75% of predicted) caused by nonobstructive hypertrophic cardiomyopathy (mean age, 55±0.26 years) were randomized to perhexiline 100 mg (n=24) or placebo (n=22). "
|5.||Aortic Valve Stenosis (Aortic Stenosis)
02/01/1997 - "Therapy with perhexiline was associated with a marked improvement in clinical status in this group of elderly patients with severe aortic stenosis."
09/01/2015 - "This study aimed to evaluate the role of perhexiline as an adjunct in myocardial protection in patients with LVH secondary to aortic stenosis (AS), undergoing an aortic valve replacement (AVR). "
02/01/1997 - "Elderly patients with symptomatic severe aortic stenosis, who were deemed unsuitable for aortic valve replacement, were treated with perhexiline, the drug dosage titrated according to steady state plasma perhexiline concentrations. "
02/01/1997 - "Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis."
01/01/2007 - "Finally, we discuss the application of pharmacogenetics in combination with therapeutic plasma monitoring to potentially broaden perhexiline's use in heart failure, aortic stenosis, and other cardiac conditions."
|1.||Creatine Kinase (Creatine Phosphokinase)
|2.||C 39 (C39)
|8.||Chlorphentermine (Chlorphentermine Hydrochloride)
|5.||Drug Therapy (Chemotherapy)